Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Hill et al v. Accentia Biopharmaceuticals, Inc. et al
Case Number:
8:13-cv-01945
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
-
February 04, 2015
$1.25M Accentia Shareholder Settlement Wins Green Light
A Florida federal judge signed off Wednesday on a $1.25 million settlement that ends a class action brought by stockholders of Accentia Biopharmaceuticals Inc. and a subsidiary accusing the companies of lying to investors about the performance of a non-Hodgkin's lymphoma treatment vaccine in development.
-
September 05, 2014
Accentia Strikes $1.25M Deal To End Investors' Vaccine Suit
An Accentia Biopharmaceuticals Inc. subsidiary agreed Friday to pay $1.25 million to settle a putative securities class action in Florida federal court accusing the company of lying to investors about the performance of a non-Hodgkin's lymphoma treatment vaccine in development that artificially inflated both companies' stock prices.
-
July 29, 2013
Accentia Faces Investor Suit Over Lymphoma Vaccine
The directors of Accentia Biopharmaceuticals Inc. subsidiary Biovest International Inc. lied to investors about the performance of a non-Hodgkin's lymphoma treatment vaccine that Biovest was developing, artificially inflating the companies' stock prices, according to a securities class action filed Friday in Florida federal court.